MCK Maintained by Leerink Partners -- Price Target Raised to $10
Leerink Partners maintained an Outperform rating for McKesson (MCK) and raised its price target from $1030 to $1070. The company's GF Value™ suggests it is 9.4% overvalued, while its GF Score™ is 80/100, indicating strong performance. McKesson, a major pharmaceutical distributor, has a market cap of $106.47B and generates over $350B in annual revenue.
How this was made
The 30-second read
Why it matters
The rating upgrade may attract short-term buying, but the overvaluation and insider sales temper expectations.
Market read
Analyst coverage change provides a modest trading signal for MCK.
What to watch
Momentum score of 3/10 suggests the stock may not rally strongly even with a higher target.
Background
McKesson is the largest pharmaceutical distributor in North America, with a market cap of ~$106B.
Ticker impact
Leerink Partners raised its price target for McKesson to $1070 and maintained an Outperform rating, providing fresh analyst coverage.
likely slight upward pressure as investors price in higher target
Target raise signals improved outlook, but momentum score is low and insider sales suggest caution.
Market effects
May lift sentiment in the healthcare distribution sector.
Limited to US markets where McKesson trades.
Low, as impact is confined to a single large distributor.
Counterpoint
Insider selling of $7M in shares could signal downside risk despite the target raise.
Key entities
- CompanyMcKesson Corp
US-listed pharmaceutical distributor (ticker MCK).
- Analyst FirmLeerink Partners
Provided the rating and price target update.
